Company profile for Polpharma Biologics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Polpharma Biologics is a leading biotechnology company specializing in developing and manufacturing biosimilar and novel biologic medicines. With state-of-the-art facilities in Poland and the Netherlands, we focus on delivering high-quality, accessible therapies to improve patient lives. Established as an independent entity in 2019, we leverage decades of pharmaceutical expertise and partner with global biopharma leaders to in...
Polpharma Biologics is a leading biotechnology company specializing in developing and manufacturing biosimilar and novel biologic medicines. With state-of-the-art facilities in Poland and the Netherlands, we focus on delivering high-quality, accessible therapies to improve patient lives. Established as an independent entity in 2019, we leverage decades of pharmaceutical expertise and partner with global biopharma leaders to innovate and expand our portfolio. At Polpharma Biologics, we are driven by a commitment to excellence, innovation, and patient care.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Poland
Address
Address
Gdansk Science & Technology Park Trzy Lipy 3, Building A 80-172 Gdansk
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251116413366/en/Polpharma-Biologics-Confirms-U.S.-Launch-of-Tyruko-natalizumab-the-First-and-Only-Biosimilar-for-Multiple-Sclerosis

BUSINESSWIRE
17 Nov 2025

https://polpharmabiologics.com/en/presentation-of-a-ranibizumab-biosimilar/

PRESS RELEASE
21 Oct 2025

https://www.businesswire.com/news/home/20250902492755/en/Polpharma-Biologics-and-MS-Pharma-Sign-Licensing-Agreements-for-Proposed-Vedolizumab-PB016-Ocrelizumab-PB018-and-Guselkumab-PB019-Biosimilars

BUSINESSWIRE
02 Sep 2025

https://www.businesswire.com/news/home/20250805925297/en/Polpharma-Biologics-and-Fresenius-Kabi-Sign-Licensing-Agreement-for-Proposed-Vedolizumab-Biosimilar-PB016

BUSINESSWIRE
13 Aug 2025

https://blog.probiogen.de/press-releases/probiogen-enters-agreement-with-polpharma-biologics?_gl=1*j0gccw*_up*MQ..*_gs*MQ..&gclid=CjwKCAjwuIbBBhBvEiwAsNypvZ6a37lhzc1JWpshLunfa2lzwk07aBWqjnjTXhTfAPV_6RIvaAoUnRoCp9oQAvD_BwE&gbraid=0AAAAApUIM1jWo96p-d1m6eNLeDizrvp9X

PRESS RELEASE
07 May 2025

https://chimebiologics.com/chime-biologics-partners-polpharma-biologics-to-advance-global-biosimilar-development/

PRESS RELEASE
17 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty